Role of personal hygiene in managing patients with vulvovaginal atrophy
https://doi.org/10.17749/2949-5873/rehabil.2025.29
Abstract
Background. Vulvovaginal atrophy (VVA) leads to sexual dysfunction and reduces the overall quality of life of affected women. At the same time, the development of individual rehabilitation programs for women with VVA remains challenging.
Objective: To study the profile of hygienic factors contributing to better control of VVA manifestations.
Material and methods. The study included 110 women with VVA of different etiologies. A questionnaire was developed to identify the connections between VVA and hygienic factors, to establish the nature and cause of clinical manifestations, and to determine the profile of measures and means used in personal vulvar hygiene.
Results. Of 110 women, 72 (65.5%) complained of vulvar itching. An analysis of the frequency of hygiene procedures and used intimate hygiene products revealed that 23.6% of the studied women wash once a day, 55.5% use special intimate gels for vulvar hygiene, and 20.0% prefer synthetic underwear.
Conclusion. The study revealed a significant proportion of VVA patients to be non-compliant with hygiene recommendations. Maintaining vulvar hygiene is one of the key factors contributing to the control of VVA manifestations. Proper information and compliance with hygiene recommendations can significantly affect the effectiveness of rehabilitation programs for women with VVA.
About the Author
O. S. Gridasova
Real Trans Hair Сlinic
Russian Federation
Russian Federation
Olga S. Gridasova
8А Yakovoapostolsky Passage, Moscow 105064
References
1. Ampilogova D.M., Solopova A.G., Blinov D.V., et al. Vulvovaginal atrophy: issues of treatment and rehabilitation: a review. Gynecology. 2022; 24 (4): 240–5 (in Russ.). https://doi.org/10.26442/20795696.2022.4.201792.
2. Orazov M.R., Silantyeva E.S., Radzinsky V.E., et al. Vulvovaginal atrophy in the peri- and post-menopause: relevance and impact on quality of life. Gynecology. 2022; 24 (5): 408–12 (in Russ.). https://doi.org/10.26442/20795696.2022.5.201854.
3. Pérez-López F.R., Vieira-Baptista P., Phillips N., et al. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecol Endocrinol. 2021; 37 (8): 740–5. https://doi.org/10.1080/09513590.2021.1931100.
4. Ermakova E.I. Genitourinary menopausal syndrome: diagnosis and treatment principles. Meditsinskiy sovet / Medical Council. 2019; 13: 106–11 (in Russ.). https://doi.org/10.21518/2079-701X-2019-13-106-111.
5. Nappi R.E., Palacios S., Panay N., et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016; 19 (2): 188–97. https://doi.org/10.3109/13697137.2015.1107039.
6. Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin Obstet Gynecol. 2015; 58 (3): 476–91. https://doi.org/10.1097/GRF.0000000000000126.
7. Fashemi B., Delaney M.L., Onderdonk A.B., Fichorova R.N. Effects of feminine hygiene products on the vaginal mucosal biome. Microb Ecol Health Dis. 2013; 24: 10.3402/mehd.v24i0.19703. https://doi.org/10.3402/mehd.v24i0.19703.
8. Chen Y., Bruning E., Rubino J., Eder S.E. Role of female intimate hygiene in vulvovaginal health: global hygiene practices and product usage. Womens Health. 2017; 13 (3): 58–67. https://doi.org/10.1177/1745505717731011.
9. Shim S., Park K.M., Chung Y.J., Kim M.R. Updates on therapeutic alternatives for genitourinary syndrome of menopause: hormonal and non-hormonal managements. J Menopausal Med. 2021; 27 (1): 1–7. https://doi.org/10.6118/jmm.20034.
10. Solopova A.G., Sandzhieva L.N., Galkin V.N., et al. Restoration of sexual function after surgical treatment for endometrial cancer. Reabilitologia / Journal of Medical Rehabilitation. 2024; 2 (2): 177–85 (in Russ.). https://doi.org/10.17749/2949-5873/rehabil.2024.11.
11. Mac Bride M.B., Rhodes D.J., Shuster L.T. Vulvovaginal atrophy. Mayo Clin Proc. 2010; 85 (1): 87–94. https://doi.org/10.4065/mcp.2009.0413.
12. Moyneur E., Dea K., Derogatis L.R., et al. Prevalence of depression and anxiety in women newly diagnosed with vulvovaginal atrophy and dyspareunia. Menopause. 2020; 27 (2): 134. https://doi.org/10.1097/GME.0000000000001450.
13. Zainetdinova L.F., Telesheva L.F., Medvedev B.I., Khakhulina V.V. Vulvovaginal atrophy: current methods of diagnosis and treatment. Bulletin of Siberian Medicine. 2024; 23 (1): 134–43 (in Russ.). https://doi.org/10.20538/1682-0363-2024-1-134-143.
14. Pérez-López F.R., Phillips N., Vieira-Baptista P., et al. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease. Gynecol Endocrinol. 2021; 37 (8): 746–52. https://doi.org/10.1080/09513590.2021.1943346.
15. Sturdee D.W., Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010; 13 (6): 509–22. https://doi.org/10.3109/13697137.2010.522875.
16. Terekhov M.A., Pustotina O.A. Urogenital disorders in women with vulvovaginal atrophy: problems and approaches to therapy (literature review). Effective Pharmacotherapy. 2022; 18 (34): 22–31 (in Russ.).
17. Matthews N., Wong V., Brooks J., Kroumpouzos G. Genital diseases in the mature woman. Clin Dermatol. 2018; 36 (2): 208–21. https://doi.org/10.1016/j.clindermatol.2017.10.012.
18. Schuiling K.D., Likis F.E. Gynecologic health care: with an introduction to prenatal and postpartum care: with an introduction to prenatal and postpartum care. 4th ed. Jones & Bartlett Learning; 2020: 500 pp.
19. Calleja-Agius J., Brincat M.P. Urogenital atrophy. Climacteric. 2009; 12 (4): 279–85. https://doi.org/10.1080/13697130902814751.
Review
For citations:
Gridasova O.S. Role of personal hygiene in managing patients with vulvovaginal atrophy. Journal of Medical Rehabilitation. 2025;3(1):22-28. (In Russ.) https://doi.org/10.17749/2949-5873/rehabil.2025.29
Views:
236
Email this article 